Clinical trials: For Oncologic Patients
Ovarian Cancer, Breast Cancer
Comprehensive Outcomes for After Cancer Health
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer.
- Conditions
- Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer
- Trial name
- COACH (NCT05349227)
- Testing
- Digital Health Coaching Program, Fitbit
- Where
- 7 sites in United States
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- Pack Health
Chemotherapy-Induced Nausea and Vomiting
Observational Study on the Use of Akynzeo® in Patients Receiving HEC
This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology…
- Trial name
- EVOLVE_CINV (NCT03649230)
- Testing
- 300mg netupitant/0.5mg palonosetron hydrochloride
- Where
- 17 sites in Canada
- Volunteers
- 207 people
- Sponsor
- Purdue Pharma, Canada
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
A Phase II Trial for MOR Antagonism With Axelopran to Enhance Immunotherapy in Head and Neck Cancer
This Phase 2, open-label, multicenter study will evaluate the safety and preliminary efficacy of axelopran in combination with pembrolizumab in patients with PD-L1 positive recurrent or metastatic head and neck squamous cell…
- Trial name
- MORALE-HN01 (NCT07662720)
- Testing
- axelopran, Pembolizumab
- Volunteers
- 18 people
- Sponsor
- Glycyx Therapeutics
Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
This study is designed to determine the efficacy and safety of durvalumab and/or novel oncology therapies, with or without chemotherapy, for first-line Stage IV Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- MAGELLAN (NCT03819465)
- Testing
- Durvalumab, Danvatirsen, Oleclumab
- Where
- 41 sites in United States, Austria and 7 more
- Volunteers
- 175 people
- Sponsor
- AstraZeneca
Breast Cancer
Improving Surgical/Medical Oncology Collaboration for Breast Cancer Treatment Planning: Pilot Testing the Impact of Continuing Education and Patient Care Planning
This study will explore provider's screening and management practices for eligibility for neoadjuvant therapy from baseline to following the project intervention (use of a novel existing technology, the Carevive Care Planning…
- Trial name
- NCT03161600
- Testing
- Carevive CPS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Carevive Systems, Inc.
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer
A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers
This Phase 1b/2a study will assess the efficacy, safety, and pharmacodynamics of CyPep-1 when administered directly into measurable tumor lesions in combination with the anti-PD-1 antibody pembrolizumab.
- Conditions
- Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
- Trial name
- Catalyst (NCT05383170)
- Testing
- CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 6 people
- Sponsor
- Cytovation AS
Colon Cancer, Breast Cancer
A Digimed Oncology PharmacoTherapy Registry
DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch (patch), and a mobile app, which records time-stamped medication type and dose alongside biometric activity.
- Conditions
- Colon Cancer, Breast Cancer, Rectal Cancer
- Trial name
- ADOPTR (NCT04088955)
- Testing
- DigiMeds
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Proteus Digital Health, Inc.
Solid Tumor, Lymphoma
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the…
- Trial name
- NCT03884556
- Testing
- TTX-030, Pembrolizumab, Gemcitabine
- Where
- 16 sites in United States
- Volunteers
- 56 people
- Sponsor
- Trishula Therapeutics, Inc.
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
To evaluate the molecular testing pattern in metastatic NSCLC patients after QIP; To evaluate the treatment pattern in metastatic NSCLC patients after QIP.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Respiratory Tract Neoplasms, Thoracic Neoplasms
- Trial name
- NCT06494241
- Where
- 46 sites in China
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Oncology
Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients
This pragmatic trial addresses the clinical gap through the generation of evidence on the comparative effectiveness between AKYNZEO® and Standard of Care (SoC, including EMEND®) in the real-life setting
- Trial name
- NCT03831633
- Testing
- Akynzeo, Standard of Care
- Where
- France
- Volunteers
- 426 people
- Sponsor
- VIFORFRANCE
Multiple Myeloma
Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma
The purpose of this study is to compare bortezomib, dexamethasone and cyclophosphamide to bortezomib and dexamethasone alone for primary refractory or relapsed multiple myeloma.
- Trial name
- NCT00813150
- Testing
- Dexamethasone, Bortezomib, Cyclophosphamide
- Where
- 40 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Janssen-Cilag G.m.b.H
Cervical Cancer
Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom
The objective of the present study is to estimate the overall survival of patients with cervical cancer after the administration of monoclonal antibody (mAb) Nimotuzumab (hR3) in combination with chemotherapy of first intention.
- Trial name
- CIMAHOPE (NCT03413579)
- Testing
- Nimotuzumab ( h-R3)
- Where
- 5 sites in Algeria
- Volunteers
- 37 people
- Sponsor
- El Kendi Pharmaceuticals Manufacturing Company
Oncology, Adherence, Medication
Evaluation of ReX-C® System for Medication Adherence in Oncology Patients Taking Oral Oncolytics
In recent decades, an increasing number of oral anticancer medications (oral oncolytics) have been approved. Oral oncolytics now make up to 30% of the oncology market, and their use is continually expanding.
- Conditions
- Oncology, Adherence, Medication, Side Effect
- Trial name
- NCT04091711
- Testing
- ReX-C system
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Dosentrx Ltd.
Multiple Myeloma, Solitary Plasmacytoma
MargheRITA (Remote Intelligence for Therapeutic Adherence)
It is essential to improve clinical efficiency and management of hematological and oncological patients treated on an outpatient basis.
- Conditions
- Multiple Myeloma, Solitary Plasmacytoma, Amyloidosis, Chronic Myeloid Leukemia
- Trial name
- MargheRITA (NCT05260203)
- Testing
- RITA (App)
- Where
- Italy
- Volunteers
- 124 people
- Sponsor
- Advice Pharma Group srl
Adenocarcinoma of the Pancreas, Advanced Solid Tumors
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
AMG 479 is an investigational fully human monoclonal antibody that targets type 1 insulin-like growth factor receptor (IGF-1R). Signaling through IGF-1R plays an important role in the regulation of cell growth and survival.
- Conditions
- Adenocarcinoma of the Pancreas, Advanced Solid Tumors, Cancer, Cancer of Pancreas
- Trial name
- GAMMA (NCT01231347)
- Testing
- AMG 479, gemcitabine
- Where
- 152 sites in United States, Australia and 30 more
- Volunteers
- 800 people
- Sponsor
- NantCell, Inc.
Multiple Myeloma, Multiple Myeloma Without Mention of Remission
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing…
- Trial name
- NCT06149910
- Testing
- Multiple Myeloma Pathway, All4Cure Platform, Documentation Pathway
- Where
- United States
- Volunteers
- 450 people
- Sponsor
- All4Cure
Adenocarcinoma, Gastric, Neoplasm, Breast
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03368196
- Testing
- DS-8201a
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Myelodysplastic Syndrome
An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome
The purpose of this study is to evaluate the effectiveness and safety of decitabine in the treatment of myelodysplastic syndrome (name of a group of conditions that occur when the blood-forming cells in the bone marrow are…
- Trial name
- NCT01751867
- Testing
- Decitabine at 15 mg/m2, Decitabine at 20 mg/m2
- Where
- 8 sites in China
- Volunteers
- 135 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Solid Tumor
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
- Trial name
- NCT06010342
- Testing
- TL118 Capsule
- Where
- 20 sites in United States, China
- Volunteers
- 60 people
- Sponsor
- Teligene US
Hyponatremia, Syndrome of Inappropriate ADH (SIADH) Secretion
An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
In 2014, the Spanish Sociedad Española de Oncología Médica (SEOM) algorithm for the treatment of hyponatraemia secondary to to syndrome of inappropriate antidiuretic hormone (SIADH) in oncology patients was developed.
- Trial name
- ALGA (NCT02548845)
- Where
- 4 sites in Spain
- Volunteers
- 70 people
- Sponsor
- Otsuka Pharmaceutical Europe Ltd